{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:19:26Z","timestamp":1789121966900,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s12185-025-04132-8","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:18:56Z","timestamp":1765610336000},"page":"544-555","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Development of a blood test-based predictive scoring tool for treatment response in chronic myeloid leukemia"],"prefix":"10.1007","volume":"123","author":[{"given":"Kohjin","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6493-6225","authenticated-orcid":false,"given":"Tomoiku","family":"Takaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyoshi","family":"Iriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisaku","family":"Iwanaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maho","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Tabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Mitsumori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Nakazato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihide","family":"Tokuhira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Hatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"issue":"5405","key":"4132_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243(5405):290\u20133. https:\/\/doi.org\/10.1038\/243290a0.","journal-title":"Nature"},{"key":"4132_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/BF01630378","volume":"8","author":"PC Nowell","year":"1962","unstructured":"Nowell PC. The minute chromosome (Phl) in chronic granulocytic leukemia. Blut. 1962;8:65\u20136. https:\/\/doi.org\/10.1007\/BF01630378.","journal-title":"Blut"},{"issue":"2","key":"4132_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.5045\/br.2022.2021173","volume":"57","author":"MA Samad","year":"2022","unstructured":"Samad MA, Mahboob E, Mansoor H. Chronic myeloid leukemia: a type of MPN. Blood Res. 2022;57(2):95\u2013100. https:\/\/doi.org\/10.5045\/br.2022.2021173.","journal-title":"Blood Res"},{"issue":"4944","key":"4132_CR4","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1126\/science.2406902","volume":"247","author":"GQ Daley","year":"1990","unstructured":"Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome. Science. 1990;247(4944):824\u201330. https:\/\/doi.org\/10.1126\/science.2406902.","journal-title":"Science"},{"issue":"3","key":"4132_CR5","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/cas.16424","volume":"116","author":"K Suzuki","year":"2025","unstructured":"Suzuki K, Watanabe N, Torii S, Arakawa S, Ochi K, Tsuchiya S, et al. BCR::ABL1-induced mitochondrial morphological alterations as a potential clinical biomarker in chronic myeloid leukemia. Cancer Sci. 2025;116(3):673\u201389. https:\/\/doi.org\/10.1111\/cas.16424.","journal-title":"Cancer Sci"},{"issue":"5","key":"4132_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2(5):561\u20136. https:\/\/doi.org\/10.1038\/nm0596-561.","journal-title":"Nat Med"},{"issue":"24","key":"4132_CR7","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851\u20137. https:\/\/doi.org\/10.1200\/JCO.2015.66.2866.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4132_CR8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3324\/haematol.2016.142877","volume":"101","author":"R Hehlmann","year":"2016","unstructured":"Hehlmann R. Innovation in hematology. Perspectives: CML 2016. Haematologica. 2016;101(6):657\u20139. https:\/\/doi.org\/10.3324\/haematol.2016.142877.","journal-title":"Haematologica"},{"issue":"11","key":"4132_CR9","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s00432-014-1746-8","volume":"140","author":"M Lauseker","year":"2014","unstructured":"Lauseker M, Hanfstein B, Haferlach C, Schnittger S, Pfirrmann M, Fabarius A, et al. Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase. J Cancer Res Clin Oncol. 2014;140(11):1965\u20139. https:\/\/doi.org\/10.1007\/s00432-014-1746-8.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"4132_CR10","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966\u201384. https:\/\/doi.org\/10.1038\/s41375-020-0776-2.","journal-title":"Leukemia"},{"issue":"8","key":"4132_CR11","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","volume":"39","author":"JF Apperley","year":"2025","unstructured":"Apperley JF, Milojkovic D, Cross NCP, Hjorth-Hansen H, Hochhaus A, Kantarjian H, et al. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia. 2025;39(8):1797\u2013813. https:\/\/doi.org\/10.1038\/s41375-025-02664-w.","journal-title":"Leukemia"},{"issue":"24","key":"4132_CR12","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251\u20139. https:\/\/doi.org\/10.1056\/NEJMoa0912614.","journal-title":"N Engl J Med"},{"issue":"10","key":"4132_CR13","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1609324.","journal-title":"N Engl J Med"},{"issue":"9","key":"4132_CR14","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.3324\/haematol.2023.284860","volume":"109","author":"S Saugues","year":"2024","unstructured":"Saugues S, Lambert C, Daguenet E, Roth-Guepin G, Huguet F, Cony-Makhoul P, et al. The initial molecular response predicts the deep molecular response but not treatment-free remission maintenance in a real-world chronic myeloid leukemia cohort. Haematologica. 2024;109(9):2893\u2013907. https:\/\/doi.org\/10.3324\/haematol.2023.284860.","journal-title":"Haematologica"},{"issue":"3","key":"4132_CR15","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3324\/haematol.2013.095158","volume":"99","author":"G Etienne","year":"2014","unstructured":"Etienne G, Dulucq S, Nicolini FE, Morisset S, Fort MP, Schmitt A, et al. Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy. Haematologica. 2014;99(3):458\u201364. https:\/\/doi.org\/10.3324\/haematol.2013.095158.","journal-title":"Haematologica"},{"issue":"16","key":"4132_CR16","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1200\/JCO.23.01647","volume":"42","author":"FX Mahon","year":"2024","unstructured":"Mahon FX, Pfirrmann M, Dulucq S, Hochhaus A, Panayiotidis P, Almeida A, et al. European stop tyrosine kinase inhibitor trial (EURO-SKI) in chronic myeloid leukemia: final analysis and novel prognostic factors for treatment-free remission. J Clin Oncol. 2024;42(16):1875\u201380. https:\/\/doi.org\/10.1200\/JCO.23.01647.","journal-title":"J Clin Oncol"},{"issue":"5","key":"4132_CR17","doi-asserted-by":"publisher","first-page":"e3309","DOI":"10.1002\/hon.3309","volume":"42","author":"D Cattaneo","year":"2024","unstructured":"Cattaneo D, Bucelli C, Bellani V, Mora B, Iurlo A. Treatment-free remission as a new goal in the management of chronic myeloid leukemia: clinical and biological aspects. Hematol Oncol. 2024;42(5):e3309. https:\/\/doi.org\/10.1002\/hon.3309.","journal-title":"Hematol Oncol"},{"issue":"12","key":"4132_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11912-017-0642-1","volume":"19","author":"AG Elsayed","year":"2017","unstructured":"Elsayed AG, Srivastava R, Jamil MO. Treatment-free remission: a new therapeutic goal in chronic myelogenous leukemia. Curr Oncol Rep. 2017;19(12):77. https:\/\/doi.org\/10.1007\/s11912-017-0642-1.","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"4132_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11899-016-0309-2","volume":"11","author":"L Caldemeyer","year":"2016","unstructured":"Caldemeyer L, Dugan M, Edwards J, Akard L. Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia. Curr Hematol Malig Rep. 2016;11(2):71\u20139. https:\/\/doi.org\/10.1007\/s11899-016-0309-2.","journal-title":"Curr Hematol Malig Rep"},{"key":"4132_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.21037\/sci.2016.07.08","volume":"3","author":"S Kimura","year":"2016","unstructured":"Kimura S. Current status of ABL tyrosine kinase inhibitors stop studies for chronic myeloid leukemia. Stem Cell Investig. 2016;3:36. https:\/\/doi.org\/10.21037\/sci.2016.07.08.","journal-title":"Stem Cell Investig"},{"issue":"4","key":"4132_CR21","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia. Blood. 1984;63(4):789\u201399.","journal-title":"Blood"},{"issue":"1","key":"4132_CR22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/leu.2015.261","volume":"30","author":"M Pfirrmann","year":"2016","unstructured":"Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30(1):48\u201356. https:\/\/doi.org\/10.1038\/leu.2015.261.","journal-title":"Leukemia"},{"issue":"11","key":"4132_CR23","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1182\/blood.V92.11.4059","volume":"92","author":"FX Mahon","year":"1998","unstructured":"Mahon FX, Faberes C, Pueyo S, Cony-Makhoul P, Salmi R, Boiron JM, et al. Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-alpha. Blood. 1998;92(11):4059\u201365.","journal-title":"Blood"},{"issue":"3","key":"4132_CR24","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","volume":"30","author":"D Marin","year":"2012","unstructured":"Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012;30(3):232\u20138. https:\/\/doi.org\/10.1200\/JCO.2011.38.6565.","journal-title":"J Clin Oncol"},{"issue":"9","key":"4132_CR25","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1038\/sj.leu.2402680","volume":"16","author":"K Merx","year":"2002","unstructured":"Merx K, Muller MC, Kreil S, Lahaye T, Paschka P, Schoch C, et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia. 2002;16(9):1579\u201383. https:\/\/doi.org\/10.1038\/sj.leu.2402680.","journal-title":"Leukemia"},{"key":"4132_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.leukres.2017.01.003","volume":"54","author":"N Iriyama","year":"2017","unstructured":"Iriyama N, Tokuhira M, Takaku T, Sato E, Ishikawa M, Nakazato T, et al. Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: surveillance of the CML Cooperative Study Group. Leuk Res. 2017;54:55\u20138. https:\/\/doi.org\/10.1016\/j.leukres.2017.01.003.","journal-title":"Leuk Res"},{"key":"4132_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-024-03758-4","author":"N Iriyama","year":"2024","unstructured":"Iriyama N, Iwanaga E, Kimura Y, Watanabe N, Ishikawa M, Nakayama H, et al. Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML cooperative study group. Int J Hematol. 2024. https:\/\/doi.org\/10.1007\/s12185-024-03758-4.","journal-title":"Int J Hematol"},{"issue":"6","key":"4132_CR28","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(6):1809\u201320. https:\/\/doi.org\/10.1182\/blood-2006-02-005686.","journal-title":"Blood"},{"issue":"35","key":"4132_CR29","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041\u201351. https:\/\/doi.org\/10.1200\/JCO.2009.25.0779.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4132_CR30","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872\u201384. https:\/\/doi.org\/10.1182\/blood-2013-05-501569.","journal-title":"Blood"},{"issue":"3","key":"4132_CR31","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"4132_CR32","doi-asserted-by":"publisher","first-page":"8931","DOI":"10.1002\/cam4.3516","volume":"9","author":"E Sato","year":"2020","unstructured":"Sato E, Iriyama N, Tokuhira M, Takaku T, Ishikawa M, Nakazato T, et al. The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort. Cancer Med. 2020;9(23):8931\u20139. https:\/\/doi.org\/10.1002\/cam4.3516.","journal-title":"Cancer Med"},{"issue":"6","key":"4132_CR33","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/wsbm.86","volume":"2","author":"J Seita","year":"2010","unstructured":"Seita J, Weissman IL. Hematopoietic stem cell: self-renewal versus differentiation. Wiley Interdiscip Rev Syst Biol Med. 2010;2(6):640\u201353. https:\/\/doi.org\/10.1002\/wsbm.86.","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"issue":"4","key":"4132_CR34","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.stem.2007.07.004","volume":"1","author":"Y Arinobu","year":"2007","unstructured":"Arinobu Y, Mizuno S, Chong Y, Shigematsu H, Iino T, Iwasaki H, et al. Reciprocal activation of GATA-1 and PU.1 marks initial specification of hematopoietic stem cells into myeloerythroid and myelolymphoid lineages. Cell Stem Cell. 2007;1(4):416\u201327. https:\/\/doi.org\/10.1016\/j.stem.2007.07.004.","journal-title":"Cell Stem Cell"},{"issue":"11","key":"4132_CR35","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(10)70233-3.","journal-title":"Lancet Oncol"},{"issue":"2","key":"4132_CR36","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s12185-017-2334-x","volume":"107","author":"N Takahashi","year":"2018","unstructured":"Takahashi N, Tauchi T, Kitamura K, Miyamura K, Saburi Y, Hatta Y, et al. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study. Int J Hematol. 2018;107(2):185\u201393. https:\/\/doi.org\/10.1007\/s12185-017-2334-x.","journal-title":"Int J Hematol"},{"issue":"7","key":"4132_CR37","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/leu.2017.63","volume":"31","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, Gomez Casares MT, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31(7):1525\u201331. https:\/\/doi.org\/10.1038\/leu.2017.63.","journal-title":"Leukemia"},{"issue":"3","key":"4132_CR38","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1016\/S2352-3026(19)30235-2","volume":"7","author":"S Kimura","year":"2020","unstructured":"Kimura S, Imagawa J, Murai K, Hino M, Kitawaki T, Okada M, et al. Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2020;7(3):e218. https:\/\/doi.org\/10.1016\/S2352-3026(19)30235-2.","journal-title":"Lancet Haematol"},{"issue":"10","key":"4132_CR39","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","volume":"18","author":"MW Deininger","year":"2020","unstructured":"Deininger MW, Shah NP, Altman JK, Berman E, Bhatia R, Bhatnagar B, et al. Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(10):1385\u2013415. https:\/\/doi.org\/10.6004\/jnccn.2020.0047.","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"4132_CR40","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1182\/blood.2020005514","volume":"137","author":"N Shanmuganathan","year":"2021","unstructured":"Shanmuganathan N, Pagani IS, Ross DM, Park S, Yong ASM, Braley JA, et al. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. Blood. 2021;137(9):1196\u2013207. https:\/\/doi.org\/10.1182\/blood.2020005514.","journal-title":"Blood"},{"issue":"6","key":"4132_CR41","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1002\/cncr.31187","volume":"124","author":"K Sasaki","year":"2018","unstructured":"Sasaki K, Kantarjian H, O\u2019Brien S, Ravandi F, Konopleva M, Borthakur G, et al. Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer. 2018;124(6):1160\u20138. https:\/\/doi.org\/10.1002\/cncr.31187.","journal-title":"Cancer"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04132-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04132-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04132-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T11:56:40Z","timestamp":1776254200000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04132-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4132"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04132-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,13]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prof. Tomoiku Takaku is an editor of IJH. All authors declare no competing financial interests regarding this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}